Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Operating Leases (2020 - 2024)

Mereo BioPharma (MREO) has disclosed Operating Leases for 5 consecutive years, with $187000.0 as the latest value for Q4 2024.

  • Quarterly Operating Leases fell 79.36% to $187000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $187000.0 through Dec 2024, down 79.36% year-over-year, with the annual reading at $187000.0 for FY2024, 79.36% down from the prior year.
  • Operating Leases for Q4 2024 was $187000.0 at Mereo BioPharma, down from $394000.0 in the prior quarter.
  • The five-year high for Operating Leases was $2.4 million in Q4 2021, with the low at $187000.0 in Q4 2024.
  • Average Operating Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 54.63% in 2021, then plummeted 79.36% in 2024.
  • Over 5 years, Operating Leases stood at $1.5 million in 2020, then skyrocketed by 54.63% to $2.4 million in 2021, then tumbled by 37.45% to $1.5 million in 2022, then plummeted by 38.74% to $906000.0 in 2023, then tumbled by 79.36% to $187000.0 in 2024.
  • According to Business Quant data, Operating Leases over the past three periods came in at $187000.0, $394000.0, and $552000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.